Document is current
Any future updates will be listed below
-
Authors
Cayssials, Emilie
Lefèvre, Lucie
Decroos, Amandine
Jacomet, Florence
Piccirilli, Nathalie
Tartarin, Florence
Guilhot, François
Chomel, Jean-Claude
Rousselot, Philippe
Nicolini, Franck E.
Ragot, Stéphanie
Gombert, Jean-Marc
Roy, Lydia
Herbelin, André
Barbarin, Alice
-
Funding
Funding for this research was provided by:
Association Sport et Collection
France intergroupe des Leucemies Myéloides Chroniques
Institut National Du Cancer (PRT-K 2015-052)
Association Laurette Fugain (ALF 2015_10)
Association pour la Recherche en Immunologie-Poitou-Charentes
Cancéropôle Grand Sud-Ouest (API-K 2017)
Ligue contre le Cancer du Grand Ouest (Comités départementaux de la Vienne, de la Charente, de la Charente Maritime et des Deux-Sèvres)
Conseil Régional Aquitaine
Fondation BMS
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 29 November 2025
First Online: 19 December 2025
Declarations
:
: The authors declare no competing interests.
: Lydia Roy, Agnès Guerci-Bresler, Martine Escoffre-Barbe, Stéphane Giraudier, Aude Charbonnier, Viviane Dubruille, Françoise Huguet, Hyacinthe Johnson-Ansah, Pascal Lenain, Shanti Ame, Gabriel Etienne, Delphine Rea, Pascale Cony-Makhoul, Stéphane Courby, Jean-Christophe Ianotto, Laurence Legros, Antoine Machet, Valérie Coiteux, Eric Hermet, Francois-Xavier Mahon, Philippe Rousselot, Franck Nicolini, Emilie Cayssials, and François Guilhot were DASA-PegIFN study investigators.
: The present work is a sub-study of the DASA-PegIFN study (EudraCT Number 2012–003389-42, ClinicalTrials.gov. NCT01872442) approved by the National Health regulatory authorities and ethical committee (Poitiers, France). This study is a prospective, nonrandomized phase 2 trial conducted in 22 centers in France.
: All the participating patients provided their written informed consent for the clinical study and ancillary biological studies.
